Who
Christopher Cabell
President & Head of R&D
Company insider
Files Form 4 as: President & Head of R&D, Inhibikase Therapeutics; CMO & Head of R&D, Zura Bio; Director, Pulmatrix; EVP, Head of R&D, and CMO, Arena Pharmaceuticals.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $884K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 12 Jun 2020
- Last trade
- 21 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Feb 2026filed 24 Feb 2026 | IKT Inhibikase TherapeuticsBiotechnology | SEC FORM 4 Code D | —338,282 at $0.00 | filing |
| 21 Feb 2026filed 24 Feb 2026 | IKT Inhibikase TherapeuticsBiotechnology | SEC FORM 4 Code D | —338,282 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,117 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,117 at $0.00 | filing |
| 21 Feb 2025filed 2 Jul 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,705 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,705 at $0.00 | filing |
| 18 May 2023filed 22 May 2023 | ZURA Zura BioBiotechnology | SEC FORM 4 Code A | —162,060 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,700 at $0.00 | filing |
| 27 Jan 2022filed 31 Jan 2022 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,100 at $0.00 | filing |
| 28 Jan 2021filed 1 Feb 2021 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 Nov 2020filed 30 Nov 2020 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 25 Nov 2020filed 30 Nov 2020 | Arena Pharmaceuticals | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 25 Nov 2020filed 30 Nov 2020 | Arena Pharmaceuticals | SEC FORM 4 Code F | $72K1,099 at $65.50 | filing |
| 15 Jul 2020filed 17 Jul 2020 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —13,000 at $0.00 | filing |
| 15 Jul 2020filed 17 Jul 2020 | Arena Pharmaceuticals | SEC FORM 4 Code M | $342K13,000 at $26.28 | filing |
| 15 Jul 2020filed 17 Jul 2020 | Arena Pharmaceuticals | SEC FORM 4 Sold | $884K13,000 at $68.00 | filing |
| 23 Jun 2020filed 25 Jun 2020 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jun 2020filed 16 Jun 2020 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.